Why perimenopause is not just a gynaecological event
Perimenopause — the transition period in which ovarian function declines and oestrogen levels become erratic before eventually falling — is routinely framed as a gynaecological event. Hot flushes. Irregular periods. Changes in libido and sleep. These are real and often significant symptoms. But they are the surface manifestation of a much more fundamental physiological shift that affects every oestrogen-sensitive system in the body — which, as it turns out, includes most of them.
Oestrogen is not simply a reproductive hormone. It has receptors on immune cells, neurons, gut epithelial cells, cardiac muscle, bone cells, and skin. It influences the transcription of hundreds of genes. It modulates inflammatory pathways, affects the composition of the gut microbiome, maintains the integrity of the intestinal barrier, and regulates the activity of the HPA stress-response axis. When oestrogen levels decline and fluctuate erratically — as they do during perimenopause — the effects propagate across every one of these systems.
"The onset of unexplained fatigue, joint pain, brain fog, and gut symptoms in a woman in her early to mid-forties should always prompt consideration of the hormonal–immune axis. These symptoms are not simply "perimenopausal". They may be the first signs of an autoimmune process that oestrogen fluctuation has unmasked."
Oestrogen, immunity, and the autoimmune threshold
Oestrogen has complex, context-dependent effects on immune function. At stable physiological levels, it tends to support immune tolerance and modulate excessive immune activity. As it fluctuates and declines, this modulating effect is lost. Regulatory T cells — the immune cells responsible for suppressing excessive immune reactivity and maintaining self-tolerance — become less active. Inflammatory cytokine profiles shift. The conditions that had been held in check by oestrogen's immunomodulatory effects may begin to break through.
This explains a consistent clinical observation: new autoimmune diagnoses cluster around the perimenopausal period in women. Rheumatoid arthritis, lupus, Sjögren's syndrome, Hashimoto's thyroiditis, primary Sjögren's, and fibromyalgia all show increased incidence or activity in the perimenopausal window. These are not coincidences. They reflect the removal of an immunomodulatory influence that had been present throughout the woman's reproductive years.
The HRT question
Hormone replacement therapy (HRT) has documented anti-inflammatory effects and may reduce autoimmune disease activity in some conditions. The decision to use HRT in the context of autoimmune disease is complex and requires coordinated input from a gynaecologist and the relevant specialist — a conversation that requires someone to facilitate it across both practitioners.
The diagnostic confusion of perimenopausal symptoms
Perimenopausal symptoms and the early symptoms of autoimmune disease overlap to a degree that creates significant diagnostic confusion. Fatigue, joint pain, brain fog, mood changes, sleep disruption, and gut symptoms are characteristic of both. A woman in her forties presenting with these symptoms may receive a perimenopausal framing from her GP, an HRT prescription, and no investigation of whether an underlying autoimmune process is active. Alternatively, she may receive autoimmune investigations without anyone connecting the timing to the hormonal transition and its immunological consequences.
What a comprehensive approach looks like
Hormonal assessment
Not simply FSH and oestradiol (which are imprecise during perimenopause), but a fuller picture including progesterone, testosterone, DHEA-S, and SHBG — assessed in context of symptoms and cycle phase.
Autoimmune antibody screening
ANA, anti-dsDNA, anti-Ro, anti-La, TPO antibodies, rheumatoid factor, and anti-CCP in women with joint symptoms — the threshold for screening should be lower in the perimenopausal window.
Thyroid depth
The perimenopausal period is associated with a significant increase in Hashimoto's diagnosis. A complete thyroid panel — TSH, free T4, free T3, and thyroid antibodies — is warranted in symptomatic women.
Gut function
Oestrogen decline alters the gut microbiome composition and may increase intestinal permeability. Gut assessment is relevant both to the perimenopausal experience and to autoimmune risk.
Inflammatory markers
A baseline inflammatory panel including hsCRP, ESR, ferritin, and homocysteine provides a reference point against which changes in disease activity can be tracked over time.
HRT discussion across specialties
The decision about HRT in the context of existing or emerging autoimmune disease requires input from gynaecology and the relevant specialist — a cross-specialty conversation that rarely happens without coordination.
The unmet need
Women navigating the perimenopausal transition with complex chronic conditions are, in most care settings, receiving either perimenopausal care or autoimmune care — rarely both in a coordinated way. The gynaecologist who manages the hormonal transition is not typically reviewing inflammatory markers. The rheumatologist or immunologist who manages the autoimmune disease is not typically assessing hormonal status or advising on HRT. The interaction between these two domains — which is, as the science makes clear, direct and clinically significant — falls into the gap between them.
Syva Health works with clients across this intersection: ensuring that the hormonal picture is assessed in the context of the autoimmune and inflammatory picture, facilitating the cross-specialty communication that the evidence demands, and holding the whole picture across what may be the most physiologically complex period in a woman's life.